Additive effects of anticoagulants: Recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma

Thrombosis and Haemostasis

Volumn 94, Issue 1, 2005, Pages 69-74

  Koestenberger, Martin ^a   Gallistl, Siegfried ^a   Muntean, Wolfgang ^a   Leschnik, Bettina ^a   Fritsch, Peter ^a   Cvirn, Gerhard ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Anticoagulation; Heparin; Melagatran; Recombinant human activated protein C; Thrombin

Indexed keywords

DROTRECOGIN; HEPARIN; MELAGATRAN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS; STUDENT T TEST; UMBILICAL CORD BLOOD;

ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL BLOOD; GLYCINE; HEPARIN; HUMANS; INFANT, NEWBORN; PROTEIN C; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN; THROMBOPLASTIN; UMBILICAL VEINS;

EID: 22144441728     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-01-0041     Document Type: Article

References (31)

1. Bernard GR, Vincent J-L, Laterre P-F et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
2. Barton P, Kalil AC, Nadel S et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004; 113: 7-17.
3. Rawicz M, Sitkowska B, Rudzinska I et al. Recombinant human activated protein C for severe sepsis in a neonate. Med Sci Monit 2002; 8: CS90-CS94.
4. Sajan I, Da-Silva SS, Dellinger RP. Drotrecogin alfa (activated) in an infant with gram-negative septic shock. J Intensive Care Med 2004; 19: 51-5.
5. Suzuki K, Stenflo J, Dahlback B et al. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-20.
6. Fulcher CA, Gardiner JE, Griffin JH et al. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V Blood 1984; 63: 486-9.
7. Dahlbäck B, Villoutreix BO. Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 1: 1525-34.
8. Scully MF, Toh CH, Hoogendoorn H et al. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 1993; 69: 448-53.
9. Cvirn G, Gallistl S, Muntean W. Alpha-2-macroglobulin inhibits the anticoagulant action of activated protein C in cord and adult plasma. Haemostasis 2001; 31: 1-11.
10. Petäjä J, Fernández JA, Gruber A et al. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 1997; 99: 2655-63.
11. van't Veer C, Golden NJ, Kalafatis M et al. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 7983-94.
12. Cvirn G, Gallistl S, Rehak T et al. Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. J Thromb Haemost 2003; 1: 1785-90.
13. Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72.
14. Gustafsson D, Antonsson T, Bylund R et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8.
15. Butenas S, van t' Veer C, Mann KG. "Normal" thrombin generation. Blood 1999; 94: 2169-78.
16. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
17. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
18. Dhainaut J-F, Yan SB, Margolis BD et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-53.
19. Dhainaut J-F, Laterre P-F, Janes JM et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29: 894-903.
20. Fernández JA, Petäjä J, Griffin JH. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C. Thromb Haemost 1999; 82: 1462-8.
21. Cvirn G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003; 1: 263-8.
22. Cvirn G, Gallistl S, Koestenberger M et al. The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma. Thromb Haemost 2004; 91: 912-8.
23. Schmidt B, Ofosu FA, Mitchell L et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-8.
24. Chan AK, Berry LR, Monagle PT et al. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002; 87: 606-13.
25. Weitz JI, Hudoba M, Massel D et al. Clot-bound thrombin is protected from inhibition by heparin-anti-thrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
26. Gustafsson D, Nyström J-E, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral pro-drug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
27. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 453-63.
28. White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol 2001; 112: 26-31.
29. Koestenberger M, Gallistl S, Cvirn G et al. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. Thromb Res 2005; 115: 135-42.
30. Koestenberger M, Cvirn G, Gallistl S et al. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 2004; 15: 693-7.
31. Frassica JJ, Vinagre YM, Maas B. Recombinant human-activated protein C (rhAPC) in childhood sepsis. J Intensive Care Med 2004; 19: 56-7.